Prostate cancer (PCa) is one of the most common malignancies in men, characterized by high incidence and recurrence rates. Despite the continuous advancement of therapeutic options for PCa, the underlying mechanisms and drug resistance issues remain a challenge for clinicians and scientists. Therefore, there is a need for an in-depth study of new advances in clinical and basic research on PCa.
Early diagnosis and personalized treatment are key factors in improving PCa patient survival and quality of life. However, due to the heterogeneity, complexity, and diversity of PCa, conventional treatments may not meet individualized patient needs. Understanding the molecular mechanisms of PCa and the impact of the tumor microenvironment (TME) on therapeutic response is important for developing new diagnostic markers and targeted therapeutic options. Additionally, while PCa genetic testing has been gradually applied in clinical practice with the development of precision medicine, there are still technical and ethical challenges that need to be addressed.
This Article Collection aims to report on the latest advancements in clinical and basic research in the field of PCa. We welcome all forms of submissions, including but not limited to the subtopics highlighted below:
- Mechanisms underlying the development of PCa and its relationship with genetic factors
- Exploring the association between the tumor microenvironment and immune therapy in PCa
- Innovations in early diagnosis and screening methods for PCa
- New breakthroughs in personalized treatment strategies and targeted therapies for PCa
Annals of Medicine accepts the following types of articles:
- Research Articles
- Review Articles
- Clinical Trials
- Protocols
- Case Series
- Commentaries
- Letter To The Editor
When submitting your article, please select the section, ‘Oncology’, and the Article Collection, ‘New Advances in Clinical and Fundamental Research on Prostate Cancer’ from the drop-down menu on the submission system.
Annals of Medicine is an online, open access, international journal publishing across all areas of medicine and is part of our Elevate Series. This means that you will receive a concierge-level publishing experience, including dedicated support from our expert in-house Editorial team, with guaranteed response times of within 48 hours, an initial decision on whether your article will be peer reviewed within 5 working days, and a first decision on your research within an average of 22 working days.
